---
title: "Is Recursion Pharmaceuticals a Warren Buffett Stock?"
description: "Recursion Pharmaceuticals, a biotech company engaged in AI-enabled drug discovery, is not typically a Warren Buffett stock due to its high R&D expenses and lack of consistent revenue. Despite these ch"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/213001912.md"
published_at: "2024-08-30T08:14:14.000Z"
---

# Is Recursion Pharmaceuticals a Warren Buffett Stock?

> Recursion Pharmaceuticals, a biotech company engaged in AI-enabled drug discovery, is not typically a Warren Buffett stock due to its high R&D expenses and lack of consistent revenue. Despite these challenges, Recursion's innovative platform may provide pathways for growth, including developing new drugs, partnerships with large pharmaceutical firms, and licensing its technology. A recent merger with Exscientia could lead to significant clinical trial insights, allowing for a potential reassessment of its investment appeal in the coming years. However, its current R&D expenses far exceed revenue, which raises concerns for traditional investors like Buffett.

**Recursion Pharmaceuticals** (RXRX 0.54%) doesn't look like a stock that legendary investor Warren Buffett would usually be interested in. It's in the biotech industry, which tends to be volatile and often difficult to understand, without significant recurring revenue or any profits for many of the newer stocks in the sector. To complicate matters further, Recursion is engaged in the emerging field of artificial intelligence (AI)-enabled drug discovery and development, which means it lacks any of the long history of consistent performance that Buffett typically looks for in an investment.

But, if the company achieves its ambitions, it could become something a lot closer to what the Oracle of Omaha prefers. Here's why it's possible and how it can happen.

## Getting around this one sticking point is part of the plan

Traditionally, Buffett doesn't favor businesses that need to spend a big proportion of their revenue on research and development (R&D) expenses. High R&D costs imply that the company doesn't have a strong enough competitive advantage with which to protect its market share from competitors. After all, if it needs to constantly improve its products or invent new ones to maintain earnings growth, it could only be a matter of time before the engine of innovation sputters out and leaves investors wanting growth.

That's part of the reason why he rarely invests in biopharmaceutical companies like Recursion. Even the best pharma players tend to spend a large proportion of their revenue on R&D, and they're far from immune to experiencing costly setbacks that disrupt the growth that shareholders had penciled in. In fact, Buffett currently doesn't hold any pharma stocks whatsoever.

However, Recursion's vision is to at least partially solve this issue at the root via both its technical innovations in drug development and its business model.

The biotech's claim to fame is its drug discovery and development platform, which heavily relies on AI, machine learning, and reams of specialized data. The point of using AI is that it can help management select and optimize the most promising candidate molecules to advance through each phase of the preclinical research process, supposedly cutting down on late-stage failures while saving money and time along the way. Ideally, its platform also translates into better clinical trial data and faster progression toward commercialization.

The jury is still out regarding whether Recursion can actually deliver those improvements over the traditional drug development approach. Still, if it does, it'll realize three distinct avenues for growth. The first is to simply develop new drugs and commercialize them on its own, whereas the second is to partner with big pharmas that want to use its platform for their own purposes, and the third is to license out access to its platform or its data trove.

And that's where Buffett's ears could start to perk up.

Licensing out access to a platform is a very low-cost way of generating revenue, and if customers are consistently deriving value from gaining access, it would point to the presence of a competitive advantage via slashing biopharma R&D costs. Furthermore, if collaborators are willing to fork over a lot of milestone payments to get more hands-on help from Recursion, there's a high chance that they'll also be willing to sign on the dotted line for the biotech to earn significant royalties from any medicines produced by the collaborations -- another low-cost revenue stream.

Finally, if -- and this is a big if -- Recursion can genuinely reduce the failure rate of its own pipeline projects compared to competitors by using its platform, it might even be able to commercialize medicines regularly enough to satisfy Buffett's desire for stable earnings growth over the long term.

## This biotech isn't in its final form yet

Time for a quick reality check. Per its Q2 earnings published on Aug. 8, Recursion's R&D expenses were $73.9 million, and its revenue was just $14.4 million. That puts its R&D expenses at more than 513% of its quarterly revenue, which is a ratio that Buffett would almost certainly find disqualifying.

Still, a lot could change over the next few years. Recursion is merging with **Exscientia**, another leading AI-enabled biotech pursuing new approaches to drug development, and between the two of them, it expects to report around 10 clinical trial readouts over the next 18 months. Each of those readouts is a (small) piece of evidence that could swing in favor or against Recursion's thesis about the effectiveness of its platform.

Within the next four years, it could get as many as four of its pipeline programs approved for sale. That means it should be possible within five years to make a more definitive judgment about the merits of its AI-based approach and its potential to deliver more revenue on a regular basis in the future.

Until then, it can't be a Buffett stock. But in the long run, if it delivers what it claims it has today, it's still quite possible that it'd meet Warren's stringent specifications.

### Related Stocks

- [RXRX.US - Recursion Pharmaceuticals](https://longbridge.com/en/quote/RXRX.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| 美股異動速遞：Abits 大漲 163.29%，Rackspace Tech 漲 64.49%，Twin Vee PowerCats 跌 54.59% | 美股市場概況當前市場呈現出明顯的強弱分化，科技股和小盤股的表現尤為突出。Abits 的暴漲引發了市場的廣泛關注，成交量大幅放大，顯示出資金的強烈介入。與此同時，部分股票如 Twin Vee PowerCats 和 Interactive S | [Link](https://longbridge.com/en/news/276477237.md) |
| OXY-Clean：巴菲特鍾愛的油井從賬面上剔除 60 億美元債務 | 西方石油公司（NYSE:OXY）在將其 OxyChem 部門以 97 億美元出售給伯克希爾哈撒韋后，顯著減少了 58 億美元的債務。這一舉措增強了其資產負債表，使總債務降至約 150 億美元。此外，西方石油將季度股息提高了超過 8%，達到每 | [Link](https://longbridge.com/en/news/276372720.md) |
| 谷歌突然發佈 Gemini 3.1 Pro：核心推理性能直接翻倍 | 谷歌發佈了最新的大模型 Gemini 3.1 Pro，其推理性能較去年發佈的 Gemini 3 Pro 翻倍。在 ARC-AGI-2 評測中，Gemini 3.1 Pro 得分 77.1%，顯示出強大的推理能力。新模型支持多源數據綜合和複雜 | [Link](https://longbridge.com/en/news/276396515.md) |
| 沃爾瑪四季度財報超預期但盈利指引不及預期，CEO 稱 “美國低收入家庭只能勉強維持生計” | 沃爾瑪 Q4 營收超預期，新財年盈利指引（每股 2.75-2.85 美元）遠低於市場預期的 2.96 美元，顯示通脹壓力下消費者支出不確定性猶存，拖累股價下跌 1.38%。財報印證 K 型” 分化：高收入家庭驅動增長，低收入羣體 “錢包吃緊 | [Link](https://longbridge.com/en/news/276398633.md) |
| GRAIL｜8-K：2025 財年 Q4 營收 43.6 百萬美元超過預期 |  | [Link](https://longbridge.com/en/news/276379877.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.